SOD1-Targeting Therapies for ALS

SOD1-Targeting Therapies

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">SOD1-Targeting Therapies for ALS</th>
</tr>
<tr>
<td class="label">ASO</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Tofersen (BIIB067)</td>
<td>Biogen/Ionis</td>
</tr>
<tr>
<td class="label">WVE-004</td>
<td>Wave Life Sciences</td>
</tr>
<tr>
<td class="label">ALSAZ-LAO-01</td>
<td>AIBSL</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Vector</td>
</tr>
<tr>
<td class="label">AAV-shRNA-SOD1</td>
<td>AAV9</td>
</tr>
<tr>
<td class="label">miRNA-based silencing</td>
<td>AAVrh.10</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Delivery</td>
</tr>
<tr>
<td class="label">CRISPR-Cas9</td>
<td>AAV</td>
</tr>
<tr>
<td class="label">Base editing</td>
<td>AAV</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ATN-224</td>
<td>Copper chelator</td>
</tr>
<tr>
<td class="label">Copper ATS</td>
<td>Copper chaperone mimic</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Arimoclomol</td>
<td>HSP90 inducer</td>
</tr>
<tr>
<td class="label">Cytosporone B</td>
<td>PGC-1α activator</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Delivery Method</td>
</tr>
<tr>
<td class="label">Recombinant SOD1</td>
<td>AAV-m

SOD1-Targeting Therapies

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">SOD1-Targeting Therapies for ALS</th>
</tr>
<tr>
<td class="label">ASO</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Tofersen (BIIB067)</td>
<td>Biogen/Ionis</td>
</tr>
<tr>
<td class="label">WVE-004</td>
<td>Wave Life Sciences</td>
</tr>
<tr>
<td class="label">ALSAZ-LAO-01</td>
<td>AIBSL</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Vector</td>
</tr>
<tr>
<td class="label">AAV-shRNA-SOD1</td>
<td>AAV9</td>
</tr>
<tr>
<td class="label">miRNA-based silencing</td>
<td>AAVrh.10</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Delivery</td>
</tr>
<tr>
<td class="label">CRISPR-Cas9</td>
<td>AAV</td>
</tr>
<tr>
<td class="label">Base editing</td>
<td>AAV</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ATN-224</td>
<td>Copper chelator</td>
</tr>
<tr>
<td class="label">Copper ATS</td>
<td>Copper chaperone mimic</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Arimoclomol</td>
<td>HSP90 inducer</td>
</tr>
<tr>
<td class="label">Cytosporone B</td>
<td>PGC-1α activator</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Delivery Method</td>
</tr>
<tr>
<td class="label">Recombinant SOD1</td>
<td>AAV-mediated</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Therapy</td>
</tr>
<tr>
<td class="label">VALOR</td>
<td>Tofersen</td>
</tr>
<tr>
<td class="label">CENTAUR</td>
<td>Arimoclomol</td>
</tr>
<tr>
<td class="label">HEALEY ALS</td>
<td>Zinbryta (CD52)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Therapy</td>
</tr>
<tr>
<td class="label">Lighthouse</td>
<td>Tofersen</td>
</tr>
<tr>
<td class="label">FUSION</td>
<td>WVE-004</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Matrix</td>
</tr>
<tr>
<td class="label">SOD1 in CSF</td>
<td>Cerebrospinal fluid</td>
</tr>
<tr>
<td class="label">[NfL](/biomarkers/neurofilament-light-chain-nfl)</td>
<td>CSF/Plasma</td>
</tr>
<tr>
<td class="label">pNfH</td>
<td>CSF/Plasma</td>
</tr>
</table>

Overview

SOD1-Targeting Therapies encompasses therapeutic approaches designed to modify the progression of SOD1-linked amyotrophic lateral sclerosis (ALS). Superoxide Dismutase 1 (SOD1) was the first gene linked to familial ALS, with over 250 pathogenic mutations identified that cause approximately 20% of familial ALS cases[@rosen1993]. The development of SOD1-targeted therapies has become one of the most advanced pipelines in ALS drug development. [@rosen1993]

SOD1 Biology in ALS

SOD1 is a metalloenzyme that catalyzes the dismutation of superoxide radicals to hydrogen peroxide. In ALS, mutant SOD1 proteins acquire toxic gain-of-function properties that lead to: [@als]

• Protein aggregation — Mutant SOD1 forms insoluble aggregates in motor [neurons](/entities/neurons)
• Mitochondrial dysfunction — Impaired energy metabolism and increased oxidative stress
• Glutamate excitotoxicity — Dysregulated glutamate transport and receptor activity
• Axonal transport defects — Impaired trafficking of proteins and organelles
• Microglial activation — Neuroinflammation driven by SOD1 aggregates

Therapeutic Approaches

Antisense Oligonucleotides (ASOs)

ASOs are single-stranded DNA molecules that bind to complementary mRNA sequences, promoting RNase H-mediated degradation of the target transcript. This reduces SOD1 protein production throughout the CNS. [@biogen]

Tofersen is the most advanced SOD1-targeting therapy. The Phase 3 VALOR study demonstrated significant reduction in SOD1 protein in CSF and a trend toward slower functional decline in fast-progressing patients[@miller2022].

Gene Therapy Approaches

AAV-Mediated RNAi

Using adeno-associated virus (AAV) vectors to deliver shRNA constructs that silence SOD1 expression.

Gene Editing

CRISPR-Cas9 approaches to directly edit mutant SOD1 alleles.

Small Molecule Inhibitors

Copper Chelation/Copper Chaperones

Since SOD1 requires copper for proper folding and function, copper modulation strategies have been explored.

Aggregation Inhibitors

Drugs designed to prevent mutant SOD1 aggregation and promote clearance.

Protein Replacement Therapy

Delivery of wild-type SOD1 protein to motor neurons to compensate for mutant SOD1 dysfunction.

Clinical Trials

Completed Trials

Ongoing Trials

Mechanism of Action

Mechanism of Action

Biomarker Monitoring

Several biomarkers are used to track SOD1-ALS progression and treatment response:

Challenges and Future Directions

Current Challenges

Emerging Approaches

• Combination therapies — ASO + small molecule for synergistic effects
• Pre-symptomatic treatment — Treating mutation carriers before disease onset
• Personalized medicine — Mutation-specific therapeutic approaches

See Also

• [SOD1 Gene](/genes/sod1)
• [SOD1 Protein](/proteins/sod1-protein)
• [ALS Genetic Variants](/diseases/als-genetic-variants)
• [ALS Therapeutics](/therapeutics/als-therapeutics)
• [Antisense Oligonucleotide Therapy](/therapeutics/antisense-oligonucleotide-therapy)
• [Gene Therapy for Neurodegeneration](/therapeutics/aav-gene-therapy-neurodegeneration)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC
• [Phase-Separated Organelle Targeting](/hypothesis/h-ec731b7a) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: G3BP1
• [Metabolic Switch Targeting for A1→A2 Repolarization](/hypothesis/h-a1b56d74) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: HK2
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypothesis/h-11795af0) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: APOE
• [DNMT1-Targeting Antisense Oligonucleotide Reset](/hypothesis/h-782e55f6) — <span style="color:#ffd54f;font-weight:600">0.45</span> · Target: DNMT1

Related Analyses:

• [CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) &#x1f504;
• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) &#x1f504;
• [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) &#x1f504;